{"transactions":[{"id":1775342,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109512,"kind":"organization","name":"Redmile Biopharma Investments II, L.P.","position":3,"cik":"0001772230","reported_name":"Redmile Biopharma Investments II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2023-09-22T01:30:28.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":498510,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by Redmile Biopharma Investments II, L.P. (the \"Fund\") and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":498510},"source":{"system":"sec-edgar","filing":"0001104659-23-102920","document":"tm2326557-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465923102920/tm2326557-1_4seq1.xml","form_type":"4"}},{"id":1775341,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109512,"kind":"organization","name":"Redmile Biopharma Investments II, L.P.","position":3,"cik":"0001772230","reported_name":"Redmile Biopharma Investments II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-09-22T01:30:28.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":432254,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by Redmile Biopharma Investments II, L.P. (the \"Fund\") and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":494687},"source":{"system":"sec-edgar","filing":"0001104659-23-102920","document":"tm2326557-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465923102920/tm2326557-1_4seq1.xml","form_type":"4"}},{"id":1775340,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109512,"kind":"organization","name":"Redmile Biopharma Investments II, L.P.","position":3,"cik":"0001772230","reported_name":"Redmile Biopharma Investments II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-09-22T01:30:28.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":864509,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by Redmile Biopharma Investments II, L.P. (the \"Fund\") and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":864509},"source":{"system":"sec-edgar","filing":"0001104659-23-102920","document":"tm2326557-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465923102920/tm2326557-1_4seq1.xml","form_type":"4"}},{"id":1775339,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109512,"kind":"organization","name":"Redmile Biopharma Investments II, L.P.","position":3,"cik":"0001772230","reported_name":"Redmile Biopharma Investments II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-22T01:30:28.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":498510,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by Redmile Biopharma Investments II, L.P. (the \"Fund\") and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1857706,"source":{"system":"sec-edgar","filing":"0001104659-23-102920","document":"tm2326557-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465923102920/tm2326557-1_4seq1.xml","form_type":"4"}},{"id":1775338,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109512,"kind":"organization","name":"Redmile Biopharma Investments II, L.P.","position":3,"cik":"0001772230","reported_name":"Redmile Biopharma Investments II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-22T01:30:28.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":494687,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by Redmile Biopharma Investments II, L.P. (the \"Fund\") and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1359196,"source":{"system":"sec-edgar","filing":"0001104659-23-102920","document":"tm2326557-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465923102920/tm2326557-1_4seq1.xml","form_type":"4"}},{"id":1775337,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109512,"kind":"organization","name":"Redmile Biopharma Investments II, L.P.","position":3,"cik":"0001772230","reported_name":"Redmile Biopharma Investments II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-22T01:30:28.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":864509,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by Redmile Biopharma Investments II, L.P. (the \"Fund\") and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":864509,"source":{"system":"sec-edgar","filing":"0001104659-23-102920","document":"tm2326557-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465923102920/tm2326557-1_4seq1.xml","form_type":"4"}}]}